PTC596

DRUG2 trials

Sponsors

PTC Therapeutics, Nationwide Children's Hospital

Conditions

CancerDiffuse Intrinsic Pontine GliomaHigh Grade Glioma

Phase 1

PTC596 in Patients With Advanced Solid Tumors

CompletedNCT02404480

PTC TherapeuticsCancer

Start: 2016-01-31End: 2017-02-06Updated: 2017-12-08

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Active, not recruitingNCT03605550

Nationwide Children's HospitalDiffuse Intrinsic Pontine Glioma, High Grade Glioma

Start: 2018-08-01End: 2029-03-01Target: 64Updated: 2026-03-27

Related Papers

DIPG-12. Induced mitotic abnormalities associated with BMI-1 modulation sensitize diffuse intrinsic pontine glioma cells to ionizing radiation

Neuro-Oncology2022-06-01

Epigentic Regulators of Glioma Stem Cells are Potential Therapeutic Targets

Neurosurgery2018-01-264 citations

Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.

Journal of Clinical Oncology2017-05-2018 citations